Exelixis, Inc. (EXEL) - Form 10-Q Summary
Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Quarterly Report (Form 10-Q)
Period Ended: September 30, 2002
Business Overview: Exelixis is a biotechnology company focused on developing proprietary human therapeutics, primarily in cancer, using an integrated discovery platform involving comparative genomics and model system genetics. The company generates revenue through collaborations with pharmaceutical, biotechnology, and agrochemical companies.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2001 |
|---|---|---|---|
| Total Revenues | $10,430 | $31,869 | $28,213 |
| Net Loss | $(22,943) | $(65,267) | $(52,917) |
| Loss Per Share (Basic & Diluted) | $(0.41) | $(1.16) | $(1.15) |
| Operating Cash Flow | N/A | $(65,047) | $(13,312) |
| Cash & Cash Equivalents | $29,336 | $29,336 | $42,813 |
| Short-term Investments | $124,891 | $124,891 | $115,779 (Proceeds) |
| Total Assets | $279,305 | $279,305 | $346,614 (Dec 31, 2001) |
| Total Liabilities | $91,153 | $91,153 | $109,394 (Dec 31, 2001) |
Liquidity: As of September 30, 2002, the company held approximately $159.1 million in cash, restricted cash, cash equivalents, and short-term investments. Management believes these resources, combined with expected funding from collaborators, are sufficient for at least the next two years.
Material Changes vs. Prior Period
- Revenue: Total revenue for the nine months ended September 30, 2002, increased to $31.9 million from $28.2 million in the prior year. This increase was driven by new collaborations (Protein Design Labs, Bristol-Myers Squibb) and compound deliveries, partially offset by the conclusion of the Pharmacia collaboration in February 2002.
- Operating Expenses: Research and development (R&D) expenses increased significantly to $84.3 million for the nine months ended September 30, 2002, compared to $59.8 million in 2001. This 41% increase was due to higher personnel costs (18% increase in the quarter, 38% in the nine months), increased lab supplies, and higher license/consulting fees.
- Net Loss: Net loss widened to $65.3 million for the nine months ended September 30, 2002, compared to $52.9 million in the prior year, primarily due to increased R&D spending.
- Goodwill Accounting: The company adopted SFAS No. 142 on January 1, 2002, discontinuing the amortization of goodwill. Consequently, amortization expense for goodwill and intangibles dropped from $3.7 million in the prior nine-month period to $0.5 million in the current period.
- Discontinued Operations: The Genomica software business was transferred to Visualize, Inc. in April 2002. Results are reported as discontinued operations, including a loss on sale of approximately $0.8 million (net of lease reversal).
Guidance, Outlook, and Risks
- Collaboration with GSK: In October 2002 (subsequent to the period end), Exelixis entered a major alliance with SmithKline Beecham (GSK). The deal includes a $30 million upfront payment, minimum $90 million in development funding over six years, and a potential loan facility of up to $85 million. Revenue recognition for the upfront fee and equity premium is expected to be approximately $4.7 million per year.
- Restructuring: In November 2002, the company implemented a restructuring plan reducing North American operations by approximately 8%. A restructuring charge of less than $1.0 million is anticipated in the fourth quarter of 2002.
- Goodwill Impairment Risk: The company noted that its market capitalization had fallen below its book value. If this persists, it may trigger a goodwill impairment charge in the fourth quarter of 2002. Goodwill carrying value was $67.4 million as of September 30, 2002.
- Profitability Outlook: The company expects to continue incurring net losses for the foreseeable future as it advances drug discovery and development programs. It anticipates needing additional capital in the future.
- Risk Factors: Key risks include dependence on collaborations, the lengthy and uncertain regulatory approval process, potential failure of clinical trials, and the need for additional financing which may be dilutive.
Investor Verification Checklist
- Goodwill Impairment: Verify if a goodwill impairment charge was recorded in Q4 2002, given the market cap/book value discrepancy noted in the filing.
- GSK Alliance Revenue Recognition: Confirm the timing and amount of revenue recognized from the GSK alliance in subsequent filings, specifically the $4.7 million annual run rate.
- Restructuring Costs: Monitor the actual restructuring charge recorded in Q4 2002 against the estimated "less than $1.0 million."
- Cash Burn Rate: Track the rate of cash consumption against the $159 million liquidity position to validate the "two-year runway" assertion.
- Clinical Progress: Verify the status of the rebeccamycin analogue Phase II trials and the timeline for the first proprietary IND filing (anticipated early 2003).